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Abstract
The N-Myc downstream-regulated gene (NDRG) family consists of four members (NDRG1, NDRG2,NDRG3, NDRG4) that are
differentially expressed in various organs and function in important processes, like cell proliferation and differentiation. In the last
couple of decades, interest in this family has risen due to its connection with several disorders of the nervous system including
Charcot-Marie-Tooth disease and dementia, as well as nervous system cancers. By combining a literature review with in silico
data analysis of publicly available datasets, such as the Mouse Brain Atlas, BrainSpan, the Genotype-Tissue Expression (GTEx)
project, and Gene Expression Omnibus (GEO) datasets, this review summarizes the expression and functions of the NDRG
family in the healthy and diseased nervous system. We here show that the NDRGs have a differential, relatively cell type–
specific, expression pattern in the nervous system. Even though NDRGs share functionalities, like a role in vesicle trafficking,
stress response, and neurite outgrowth, other functionalities seem to be unique to a specific member, e.g., the role of NDRG1 in
myelination. Furthermore, mutations, phosphorylation, or changes in expression of NDRGs are related to nervous system
diseases, including peripheral neuropathy and different forms of dementia. Moreover, NDRG1, NDRG2, and NDRG4 are all
involved in cancers of the nervous system, such as glioma, neuroblastoma, or meningioma. All in all, our review elucidates that
although the NDRGs belong to the same gene family and share some functional features, they should be considered unique in
their expression patterns and functional importance for nervous system development and neuronal diseases.
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Introduction
The N-myc downstream–regulated gene (NDRG) family con-
sists of four members: NDRG1, NDRG2, NDRG3, and
NDRG4. The name of this family originates from the first gene
discovered, NDRG1, as this gene can be repressed by the c-
myc andN-Myc proto-oncogenes. However, even though each
family member has been given a similar name, they are not all
(in)directly regulated by either c- or N-myc [1, 2]. NDRG
proteins share 57–65% amino acid identity and they all have
an α/β hydrolase-fold region without hydrolytic catalytic ac-
tivity [2, 3]. For a detailed review about the structure, origin,
and function of the NDRG family, we refer to our previous
review [2]. Briefly, all family members are functionally in-
volved in cell proliferation, apoptosis, differentiation, devel-
opment, and stress response, with NDRG1 and NDRG2 being
extensively investigated in the context of cancer [4–6].
Generally, the NDRGs are considered to be tumor suppressor
genes, by inhibiting proliferation and enhancing apoptosis
through regulation of e.g. p53-, TGF-β-, and Wnt-signaling
[7–9].
We previously identified NDRG4 promoter methylation as
a biomarker for the detection of colorectal cancer, and we
observed that NDRG4 is specifically expressed in neuronal
cell bodies and nerve fibers in the intrinsic nervous system
of the gut: the enteric nervous system (ENS) [10]. Next to
NDRG4, NDRG2, and NDRG3 are also expressed in enteric
neural crest cells, the precursors of the ENS, during intestinal
maturation, but their expression shifts towards other cell types
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in the adult gut [11]. Besides the role of NDRG4 in colorectal
cancer, NDRG4 and the other NDRGs have also been de-
scribed to be involved in nervous system cancers, like menin-
gioma, neuroblastoma, and glioma. Moreover, all NDRG
genes are expressed in nervous system structures and seem
to be involved in the development and physiology of the ner-
vous system [1]. All this addresses a potential importance for
the NDRGs in the central and peripheral nervous system.
To learn more about the role of the NDRG family in the
(patho)physiology of the nervous system, we performed an
extensive literature search using Embase, Medline, Web of
Science, and PubMed and validated these findings with in
silico analyses using publicly available datasets, such as the
Mouse Brain Atlas, the Genotype-Tissue Expression (GTEx)
project (18/03/2019), and Gene Expression Omnibus (GEO)
datasets (GSE9566 and GSE35366).
Expression during development
The NDRG family members have different temporal expres-
sion patterns during the embryological phase and further de-
velopment, suggesting that each member serves distinct pur-
poses during development.
Detecting the mouse-analogues of NDRG1, NDRG2, and
NDRG3, Okuda et al. found differences in mRNA expression
patterns between the individual family members in the central
nervous system (CNS). NDRG3 was expressed relatively ear-
ly in the embryological phase, around embryonic day 9.5
(E9.5), while NDRG1 and NDRG2 expressions only arose
around E12.5 and E13.5. NDRG1 was strongly expressed in
the cerebral cortex, while NDRG2 was specifically expressed
around the ventricular zone in cerebrum and spinal cord [12].
Embryonic protein expression of NDRG2 was observed in the
outer layer of the cortex, the choroid plexus, and the epidermis
from E13.5 onward. In the adult mouse, this expression pat-
tern changed to a more widespread distribution, particularly in
the midbrain, cerebellum, and pons [13]. The expression of
NDRG2 was low, but widespread, in mouse and human fetal
brain, and rose during postnatal development [14, 15].
NDRG3 showed a broader expression pattern, both in cerebral
cortex and spinal cord in mouse [12].
The spatial expression pattern of the NDRG family in the
CNS was also observed in Xenopus tropicalis [1]. NDRG1
expression was mostly found in the forebrain, which later
develops into the cerebrum, whereas NDRG2, NDRG3, and
NDRG4 expressions were found in the developing brain and
spinal cord. However, temporal expression patterns differed
from the mice studies, as NDRG3 was expressed latest during
development (gastrula stage 23) compared with the other fam-
ily members (maternal expression in eggs) in Xenopus
tropicalis [1]. In a time series of wild-type mouse brain sam-
ples from E14 to postnatal day 14 (P14), the expression of all
NDRGs except for NDRG1 rises during maturation (Fig. 1a)
[16]. The same pattern can be seen in human brain samples
from the BrainSpan project, ranging from the early prenatal
period to adulthood [17, 18]. The expression of NDRG1 re-
mains relatively low in the brain overall; NDRG2 expression
initially increases, but declines after early childhood, while the
expression of NDRG3 and NDRG4 increases over time (Fig.
1b).
Postnatally, NDRG1 was expressed in the hippocampus
from birth to P14 in rats, after which expression disappeared
in the neurons of the hippocampus and arose in astrocytes in
the caudate-putamen region in proximity to neurons. This
could reflect the differentiation that hippocampal neurons
and astrocytes undergo, as hippocampal neurons go through
morphological and metabolic changes in the first two postna-
tal weeks when NDRG1 is expressed, after which NDRG1
expression arises in mature GFAP-positive astrocytes. This
suggests that NDRG1 could play a role in the process of dif-
ferentiation [19].
In zebrafish, ndrg4 was exclusively expressed in the heart,
CNS, and sensory system during embryonic development
[20]. The ubiquitous expression of ndrg4 in the CNS changed
towards a more specific expression pattern in the cranial gan-
glia, hindbrain neurons, tegmentum, and cerebellum at 22–
72 h post-fertilization [20]. Other studies investigating the
expression profile of NDRG4 in rats identified six different
NDRG4 transcript variants, three of which lack exon 18. The
variants without exon 18 were detected in embryonic and
early postnatal brains, the others in maturing and adult brains
[21]. Using Western blotting, Nakada et al. detected a fourth
NDRG4 protein isoform in rat brain, which also shows differ-
ential expression at various developmental time points [22].
Overall, NDRG4 expression was found to be more abundant
during the adult phase, when compared with the expression
during the fetal phase in rats and humans [23].
The spatial expression patterns of the NDRG family mem-
bers during embryology are summarized in Table 1. NDRG1
expression is mainly restricted to the cerebrum during devel-
opment, while NDRG2, NDRG3 and NDRG4 are also
expressed in the spinal cord. Temporally, the expression of
the NDRGs generally increases in the brain throughout devel-
opment. Together, these expression data suggest that they
might have a role in developmental or differentiation
processes.
Cellular expression
The expression patterns of the four NDRG familymembers do
not only differ during embryologic development; their cellular
distribution in the CNS and peripheral nervous system (PNS)
during adulthood varies as well. Within the mouse brain,
NDRG1 is strongly expressed in oligodendrocytes and
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ependymal cells in the cerebrum (cortex), and weaker in
Purkinje cel ls in the cerebel lum (Fig. 2a) [24] .
Oligodendrocyte localization was also observed in rats [25].
Moreover, NDRG1 is detected in the PNS, where it is mainly
found in the cytoplasm of myelinating Schwann cells in rats,
mice, and humans [25–27].NDRG1 is mainly expressed in the
myelinating cell types which could be confirmed using the
Mouse Brain Atlas and a GEO dataset (GSE9566) containing
different types of CNS cells [28, 29]. NDRG1mRNA expres-
sion was found in myelinating and mature oligodendrocytes
(Fig. 2b) and Schwann cells, but also in satellite glia, enteric
glia, and nitrergic enteric neurons (Fig. 2c) [28].
NDRG2 is strongly expressed in glia, as shown by its co-
localization with glial fibrillary acidic protein (GFAP) in mice.
NDRG2 has even been proposed as a specific marker for
mature, non-reactive astrocytes, instead of or in addition to
GFAP detection [30]. Mainly, astrocytes in the cerebrum and
Bergmann glia in the cerebellum show cytoplasmic NDRG2
staining [24]. Shen et al. confirmed this and detected strongest
NDRG2 levels in the midbrain and thalamus. The cerebral
cortex, olfactory bulb, and hippocampus were also NDRG2-
positive [31]. On RNA level, NDRG2 is mostly expressed in
astrocytes in the CNS (Fig. 2b) [29]. Using the Mouse Brain
Atlas, we found NDRG2 expression in fibrous astrocytes,
GFAP-positive glia, and satellite glia. Interestingly, also sym-
pathetic neurons of the PNS (noradrenergic and cholinergic)
express NDRG2 (Fig. 2c) [28]. In humans, the expression
pattern ofNDRG2 is similar to mice, i.e., widespread through-
out the CNS, including mRNA expression in cerebral cortex,
striatum, cerebellum, brain stem, and spinal cord (Fig. 2a)
[14]. NDRG2 protein is specifically localized in the majority
of astrocytes, as shown by co-localization with GFAP and
S100 calcium-binding protein B (S100β) and lack of co-
localization with the neuronal marker microtubule-associated
protein 2 (MAP2) and neuron-specific enolase (NSE) in the
brain [30]. On the contrary, NDRG2 was not only detected in
Fig. 1 Temporal expression patterns of the NDRG family members
during development. a Expression in developing wild-type mouse brain
at three time points: embryonal day 14 (E14), postnatal day 0 (P0), and
postnatal day 14 (P14). Expression values are Robust Multi-array
Averages (RMA), corrected for background, log2 transformed, and
quantile-normalized. Data were obtained from GEO (GSE35366) and
analyzed using R (version 3.5.3). b Expression of the NDRGs in
human brain samples throughout development, ranging from early
prenatal stage to adulthood. Expression values are expressed as Reads
per Kilobase Million (RPKM) ± SEM. Data were obtained from
BrainSpan (http://www.brainspan.org/) and analyzed using the R2
Genomics Analysis and Visualization Platform (https://hgserver1.amc.
nl/cgi-bin/r2/main.cgi).
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GFAP-positive astrocytes but also in neuronal nuclei (NeuN)–
positive neurons in human fetal brain at gestational week 28
[15]. Thus, NDRG2 is predominantly, but not exclusively,
expressed in astrocytes in the nervous system.
Although NDRG1 and NDRG2 share a cytoplasmic local-
ization in CNS and PNS cells, NDRG3 is mainly localized in
the nucleus. Its expression is strongest in neurons, as con-
firmed by a double staining with NeuN in mice. Cerebellar
Purkinje cells and granule cells were also NDRG3-positive,
although the latter to a lesser extent [24]. Overall, NDRG3
mRNA expression is strongest in the cortex, mostly in excit-
atory neurons, and in hindbrain, mostly in excitatory, cholin-
ergic, and serotonergic neurons (Fig. 2c) [28].
We and others observed that NDRG4 has a similar expres-
sion pattern as NDRG3 (e.g., cerebral neurons, cerebellar
Purkinje cells), but is specific to the cytoplasm [10, 24].
NDRG4 always co-localizes with the neuronal marker HuC/
D and NeuN, but never with the glial marker GFAP, indicating
its specific neuronal expression [10], which is confirmed by
the highest expression of NDRG4 mRNA in neurons in the
brain (Fig. 2b). NDRG4 is almost exclusively expressed in
nervous system structures throughout the body, including the
CNS, PNS, and ENS. Within the CNS, NDRG4 mRNA and
protein expression was observed in the cerebrum, namely the
cerebral cortex, mesencephalon, pons and medulla oblongata,
the cerebellum (Purkinje cells), and the spinal cord (Fig. 2a)
[10, 23]. In mice, NDRG4mRNA expression is highest in the
peripheral sensory neurons in the dorsal root ganglion,
sympathetic neurons, and excitatory and cholinergic hindbrain
neurons in the CNS (Fig. 2c) [28].
Overall, the NDRG familymembers seem to have a distinct
cellular organization in the nervous system. NDRG1 is mainly
constricted to myelinating cell types (e.g., oligodendrocytes
and Schwann cells); NDRG2 mostly localizes in astrocytes in
the CNS, while NDRG3 and NDRG4 are mainly detected in
neurons. Although NDRG1, NDRG2, and NDRG4 share a
cytoplasmic expression pattern, NDRG3 is specifically locat-
ed in the nucleus. These variable expression patterns might
explain some of the functional differences between the family
members, which will be discussed below.
Functions
Although limited functional research within the PNS and CNS
has been done on theNDRG1 gene, it has been linked to nerve
myelination, stress response, lipid biosynthesis and metabo-
lism, exocytosis, and differentiation [32]. As described above,
NDRG1 is exclusively expressed by myelinating cell types
(e.g., Schwann cells within the PNS and oligodendrocytes
within the CNS). In addition, mutations in NDRG1 are known
to cause a peripheral neuropathy related to demyelination,
namely Charcot-Marie-Tooth disease type 4D (CMT4D),
which we will further discuss in detail in the next section
[25, 33]. Rosalind et al. investigated the function of NDRG1
in relation to myelination using both hypomorphic NDRG1
knockout (KO) mice and mice with a complete deficiency of
NDRG1 (the stretcher mouse (str.)) [34]. In both models, ini-
tial myelination was normal, but axonal damage arose after 3–
5 weeks, which resulted in decreased nerve conduction veloc-
ity. Interestingly, the str. model had a markedly more severe
phenotype, suggesting that even a very low expression of
NDRG1 can partly rescue the phenotype.
Differential expression analysis between healthy peripheral
nerves and NDRG1-deficient nerves revealed that NDRG1 is
involved in lipid trafficking. Moreover, NDRG1 is a partner
protein of Prenylated Rab Acceptor 1 (PRA1), required for
vesicle trafficking from the Golgi complex [34]. This indicates
that NDRG1 could be one of the CMT-associated proteins
involved in endosomal transport mechanisms, like SH3TC2
in CMT4C [35].
NDRG1 also has an important role in lipid metabolism,
which is a crucial process for the formation of myelin [36].
Pietiäinen et al. first studied the influence of NDRG1 on lipid
transport in epithelial cells [37]. They found a decrease in low-
density lipoprotein (LDL) uptake upon silencing of NDRG1
using small interfering RNAs (siRNA). This was caused by a
reduced abundance of LDL-receptors on the plasma mem-
brane. The same effect of NDRG1 silencing on LDL traffick-
ing was found in mouse oligodendrocytes, which elucidates a
role for NDRG1 in normal lipid and cholesterol trafficking. In
Table 1 Spatial expression of the NDRGs during development in
several species
Gene name Species Expression area
NDRG1 Xenopus tropicalis [1] Forebrain
Rat [19] Hippocampus
Caudate-putamen
NDRG2 Xenopus tropicalis [1] Brain
Spinal cord
Mouse [12, 13] Ventricular zone cerebrum
Spinal cord
Choroid Plexus
NDRG3 Xenopus tropicalis [1] Brain
Spinal cord
Mouse [12] Cerebral cortex
Spinal Cord
NDRG4 Xenopus tropicalis [1] Brain
Spinal cord
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addition, the differentiation factor oligodendrocyte lineage
transcription factor 2 (Olig2) was downregulated in NDRG1
deficient oligodendrocytes, suggesting that NDRG1 is also
involved in oligodendrocyte differentiation.
Moreover, NDRG1 has a role in stress conditions. NDRG1
is the substrate of serum/glucocorticoid-regulated kinase 1
(SGK1), which is activated by plasma corticosterone.
Expression and activation of SGK1 increase specifically in
oligodendrocytes in response to increased plasma corticoste-
rone levels and causes an increase in NDRG1 phosphoryla-
tion. This leads to different downstream effects, including
increased expression levels of the main adhesion molecules,
e.g., N-cadherin, α-catenin, and β-catenin, and altered mor-
phology of oligodendrocytes. Repeated exposure to stress led
to excess arborization of oligodendrocyte processes in mice,
and addition of the synthetic glucocorticoid dexamethasone to
cultured oligodendrocytes caused an increase in their cell size.
The same effect was established by overexpressing active
SGK1 and phosphorylated NDRG1, implicating that the mor-
phological changes are a result of the stress-induced SGK1-
NDRG1 pathway [38, 39]. It is evident that NDRG1 is an
important protein in myelinating cell types, with functions
ranging from maintenance of myelination and lipid transport
to oligodendrocyte differentiation and stress-response.
As mentioned above, NDRG2 is predominantly expressed
in astrocytes in the CNS. Gene silencing of NDRG2 in cul-
tured mouse astrocytes increased proliferation while NDRG2
overexpression inhibited proliferation, suggesting that
Fig. 2 Spatial expression patterns of the NDRG genes in nervous system
tissues and cell types. aRNA sequencing expression of the NDRG family
members in the tibial nerve and different brain regions (human). The data
used for the analyses were obtained from the GTEx project (v7) on 18/03/
2019. TPM = Transcripts Per kilobase Million ± SEM. b Affymetrix
GeneChip array expression analysis of the NDRG family members per
cell type. Expression values are normalized using MAS5.0, data obtained
from GEO (GSE9566). c Single-cell RNA sequencing expression of the
NDRG family members in the nervous system. The data used for the
analyses were obtained from http://mousebrain.org/genesearch.html on
October 5, 2019. Abbreviations in b, c are as follows: Myelin OLs,
myelinating oligodendrocytes; OLs, oligodendrocytes; OPCs,
oligodendrocyte precursor cells; ENS, enteric nervous system; Exc N,
excitatory neurons; MB Inh, midbrain inhibitory neurons; Str, striatum;
Hyp, hypothalamus; BG, basal ganglia (thalamus and pallidum); OB,
olfactory bulb; CB, cerebellum; SC, spinal cord; PNS, peripheral
nervous system; Vasc, vascular cells
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NDRG2 suppresses proliferation in astrocytes [40].
Furthermore, NDRG2 might influence astrocyte morphology,
asNDRG2 silencing caused the formation of shorter processes
and reduced F-actin content [40]. The antiproliferative func-
tion of NDRG2 was also observed in C6-originated astrocytes
(differentiated C6 glioma cells). Li et al. investigated the in-
volvement of NDRG2 during p53-induced apoptosis seen in
cerebral ischemia/reperfusion injury. Silencing of NDRG2 in
cultured astrocytes alleviated the apoptotic effect of oxygen-
glucose deprivation while overexpression of NDRG2 aug-
mented apoptosis via changes in the Bax/Bcl-2 ratio (apopto-
sis-promoting and apoptosis-suppressing mitochondrial mem-
brane proteins). Furthermore, oxygen-glucose deprivation re-
sulted in a p53-dependent upregulation of NDRG2 and trans-
location of NDRG2 to the nucleus [41]. Upregulation of
NDRG2 was also seen in rat brain directly after cerebral is-
chemia, after which NDRG2 levels declined again [42].
Another s tudy revealed a role for NDRG2 in
gliotransmission, as an indirect modulator of kainate receptor
subunit expression. Like NDRG1, NDRG2 is a substrate of
SGK1. NDRG2 phosphorylation was found to suppress the
SGK1-induced increasedmembrane expression of the glutamate
receptor subunit GluK2 in rat primary astrocytes. SGK1 is up-
regulated during stress and NDRG2 might attenuate the stress
response by preventing an excessive incorporation of GluK2 in
the membrane [43]. This could be a potential mechanism as to
why the expression of the glutamate transporters glutamate as-
partate transporter (GLAST) and glutamate transporter 1 (GLT-1)
were increased by deletion of NDRG2. An alternative explana-
tion would be that the increased expression of glutamate trans-
porters was caused by increased activation of Akt-signaling, as
NDRG2 silencing resulted in increased levels of p-Akt [44].
Finally, the role of NDRG2 on the formation of neuronal
structures has been investigated in NGF-treated PC12 cells.
Takahashi et al. observed an increase in NDRG2 mRNA ex-
pression during neurite outgrowth.Moreover, NDRG2 protein
localized specifically to the cell membrane and growth cones,
and overexpression of NDRG2 in these cells caused neurite
elongation. This suggests that NDRG2 could play a role in the
formation of (neuronal) processes [45].
The function of NDRG3 within the nervous system has
barely been investigated. NDRG3 appears to be a hypoxia-
responsive gene that is upregulated during cerebral ischemia
in rats. Resembling NDRG2, its expression rises during the
first phases of ischemic injury/hypoxia and diminishes after
the injury [46]. This could correspond to the upregulated ex-
pression of other neuroprotective genes during hypoxia, such
as VIP and PACAP [47]. NDRG3 might thus function as a
neuroprotective protein, although other functions of NDRG3
in the nervous system remain to be elucidated.
Only recently, the function of NDRG4 in the nervous sys-
tem has been investigated showing that ndrg4 plays a promi-
nent role in signal transduction via myelinated axons in
zebrafish [48]. Ndrg4-deficiency impaired the physiological
function of the nodes of Ranvier, which cluster sodium chan-
nels to ensure fast transduction. Sodium channel clustering
was nearly absent in ndrg4mutants, leading to impaired signal
transduction, even though myelination of the axon was intact.
QPCR, Western blot, and immunohistochemistry revealed
that ndrg4 regulates some key genes of the vesicle docking
pathway, e.g., synaptosomal-associated protein 25 (Snap25).
Defective vesicle docking due to ndrg4 knockdown was at
least partially responsible for the impaired sodium channel
clustering. Ndrg4 thus functions in vesicle release and plays
a fundamental role in the development and organization of
myelination in the peripheral nervous system in zebrafish
[48].
Yamamoto et al. used an NDRG4KO mouse model to in-
vestigate its effects on the nervous system. The cortex of
NDRG4KOmice contained lower levels of brain-derived neu-
rotrophic factor (BDNF), which led to impaired spatial learn-
ing and memory in the Morris water maze [49]. The associa-
tion between NDRG4 and BDNF was further investigated in
rat brain, where ischemic injury initially upregulated NDRG4
expression, but ultimately caused decreased levels of NDRG4
and a concomitant decrease in BDNF levels. Upregulation of
NDRG4 through injection with an adenoviral vector rescued
BDNF levels [50]. This indicates that NDRG4 is necessary for
the maintenance of BDNF levels.
NDRG4 is also involved in p53-mediated apoptosis in is-
chemic injury in rats. After an initial increase of NDRG4,
decreased levels of NDRG4 were observed, resembling the
expression of NDRG2 and NDRG3 during cerebral ischemia.
Upregulation of NDRG4 after ischemic injury could suppress
neuronal apoptosis by decreasing Bax expression in mito-
chondrial fractions and by inhibiting the direct interaction
with p53, as shown by co-immunoprecipitation [51].
NDRG4 thus seems to be involved in regulation of apoptosis
in the brain.
Similar to the role of NDRG2, NDRG4 is also upregulated
during neuronal differentiation of PC12 cells. Silencing of
NDRG4 resulted in inhibition of neurite outgrowth through
the suppression of activator protein 1 (AP-1) transcription
factor activation [52, 53]. NDRG4 is likely important for neu-
ronal differentiation, possibly by increasing phosphorylation
of ERK1/2, downstream targets in the MAPK/ERK pathway,
the major pathway that induces neuronal differentiation [54].
Thus, NDRG2 and NDRG4 seem to be positive regulators of
neurite outgrowth and PC12 neuronal differentiation.
Even though the NDRG family members share roughly
60% amino acid identity, their cellular expression in the ner-
vous system is distinct and so are many of their functions. As
NDRG1 is specifically expressed in myelinating cell types, it
is not surprising that it plays a role in myelination, possibly
through regulation of lipid metabolism. NDRG2 is mostly
investigated for its effect on proliferation and apoptosis, and
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appears to repress proliferation in astrocytes. NDRG3 appears
to play a role in ischemia where it could act as a neuroprotec-
tive gene. NDRG4 seems to be involved in vesicle trafficking
and apoptosis after ischemic injury. In addition, some func-
tions are shared, like the role of NDRG1 and NDRG2 in stress
response and the involvement of NDRG2 and NDRG4 in
neurite outgrowth. NDRG2, NDRG3, and NDRG4 also seem
to be involved in brain ischemia. A schematic overview of the
pathways influenced by NDRG1, NDRG2, and NDRG4 are
shown in Fig. 3a. Shared functional pathways involving more
than one NDRG family member are shown in Fig. 3b.
Association with pathologic conditions:
nervous system malignancy
Charcot-Marie-Tooth disease type 4D
Charcot-Marie-Tooth disease type 4D (CMT4D), also referred
to as hereditary motor and sensory neuropathy-Lom
(HMSNL), is a peripheral neuropathy that primarily occurs
in the Gypsy community. The autosomal recessive disease
usually results from a homozygous R148X mutation in
NDRG1, but can also be caused by other mutations in
NDRG1, such as IVS8-1G>A, or frameshift mutations [55].
Although the NDRG1 mutation R148X generally only affects
the PNS, two cases in a non-Gypsy family showed white
matter abnormalities in the CNS [56]. The disease is clinically
characterized by muscle weakness, sensory loss, and neural
deafness. Pathologic alterations include Schwann-cell dys-
function with “onion bulbs”, leading to hypomyelination and
demyelination/remyelination [27]. In a rat model investigating
de- and remyelination, the sciatic nerves that were transected
(to prevent regeneration) show decreased NDRG1 mRNA
levels, while sciatic nerves that were crushed (where regener-
ation was possible) have reduced NDRG1 mRNA expression
shortly after the injury, which returns to normal after
remyelination is complete [25]. This indicates that the expres-
sion pattern of NDRG1 correlates to the myelin content.
Owing to the fact that NDRG1 is specifically expressed by
myelinating glia such as oligodendrocytes and Schwann cells,
it can be expected that the expression of mutant NDRG1 pro-
tein contributes to the pathogenesis of such a demyelinating
neuropathy [25]. The other family members do not seem to
play a role in demyelinating neuropathies, as they are not, or to
a far lesser extent, expressed in myelinating cell types.
Alzheimer’s disease
Alzheimer’s disease (AD) is a form of dementia characterized
by two main pathological hallmarks, namely accumulation of
intracellular neurofibrillary tangles and senile plaques [57].
Interestingly, NDRG2 was found to be one of the most
pronounced upregulated genes in hippocampi of AD patients
compared with healthy controls. Mitchelmore et al. investigat-
ed the expression of NDRG2 in human hippocampal biopsies
from eight patients with confirmed late onset AD and five
controls. Both RNA and protein expression of NDRG2 were
found to be elevated twofold in AD-affected brains compared
with healthy control brains. Expression of NDRG2 was local-
ized to cortical pyramidal neurons, dystrophic neurons, and
senile plaques, which are all affected by AD [14]. Similarly,
the expression level of NDRG2was also increased in a genetic
rat model of AD [58]. One of the proposed mechanisms how
NDRG2 can affect AD pathogenesis is that neuronal cell death
can be induced by NDRG2-phosphorylation through death-
associated protein kinase 1 (DAPK1) activation. DAPK1 is
activated by senile plaques and ceramide and has a higher
expression in human AD brain samples, as well as NDRG2-
phosphorylation levels [59]. The effect of NDRG2-
phosphorylation on neuronal proliferation has not been inves-
tigated elsewhere, so further research is necessary to clarify
the exact role of NDRG2 on neuronal degeneration. Another
possibility is that NDRG2 influences amyloid precursor pro-
tein (APP) metabolism or amyloid β-plaque formation.
NDRG2 expression was found to be higher in aged rats and
rats with injected Aβ1-42, a model for AD. NDRG2 silencing
led to a decrease in Aβ1-42 (the predominant form of amyloid
β found in AD) in neuroblastoma cells, and overexpression to
an increase in Aβ1-42, implicating NDRG2 in the formation of
senile plaques. Moreover, tau-phosphorylation, the primary
mechanism of neurofibrillary tangle-formation, was upregu-
lated by NDRG2 [60]. This suggests that NDRG2 is important
in both main pathological alterations in AD.
In contrast, NDRG3 and NDRG4 were found to be down-
regulated in AD patients’ brains [61, 62], which could be
related to the decrease in BDNF levels that was seen in e.g.
NDRG4KOmice [49]. Despite these findings, no further stud-
ies have been done to investigate the role of these family
members in AD.
Frontotemporal lobar degeneration
Frontotemporal lobar degeneration (FTLD) is a neurodegen-
erative disease that mostly leads to abnormal behavior, per-
sonality changes, and language dysfunction. Using a
phosphoproteomic analysis on postmortem human brain tis-
sue from FTLD and age-matched controls, Herskowitz et al.
found that NDRG2 and GFAP phosphorylation were in-
creased compared with controls [63]. Considering that
NDRG2 and GFAP are proposed as markers for fibrous astro-
cytes, these findings implicate that fibrous astrocytes could be
of importance in FTLD. However, as cause-consequence is
difficult to assess in these studies, it is unclear whether
NDRG2-phosphorylation actively participates in FTLD
pathology.
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Multiple sclerosis
Multiple sclerosis is a demyelinating disease, disrupting the
commun i c a t i on be tween pa r t s o f t h e ne rvou s
system.NDRG2 was investigated in the context of neuroin-
flammation, using an NDRG2KO mouse in an experimental
model of multiple sclerosis (experimental autoimmune en-
cephalomyelitis (EAE)). Deletion of NDRG2 reduced clinical
symptoms of EAE. Although it had minor effects on inflam-
mation, NDRG2-deficiency caused neurodegeneration in the
acute phase of EAE and also affected oligodendrocytes in the
chronic phase. The protecting effect of NDRG2 can be ex-
plained by its role in glutamate receptor restoration. In fact,
the reduced glutamate receptor expression and concomitant
glutamate toxicity in EAE can be counteracted by the
NDRG2-induced upregulation of glutamate aspartate trans-
porter (GLAST) and glutamate transporter 1 (GLT-1). Due
to this, demyelination and neurodegeneration, the characteris-
tic features in multiple sclerosis, were significantly reduced
[44].
Meningioma
Meningiomas, which are neoplasms originating from arach-
noid cells, represent a significant proportion of all primary
nervous system neoplasms. Although meningiomas are most-
ly benign, around 15% of meningiomas are aggressive and
exhibit the potential to invade the normal brain tissue and to
frequently and destructively recur [64]. TheWHO has defined
three grades, namely benign (grade I), atypical (grade II), and
anaplastic/malignant (grade III) meningiomas, representing
about 80%, 15–20%, and 1–3%, respectively [65].
NDRG2 expression has been linked with tumor grade and
tumor recurrence. Using qPCR, Skiriute et al. investigated
NDRG2 expression in 35 patients with primary and recurrent
meningiomas. Recurrent meningiomas displayed a statistical-
ly significant reduction in NDRG2 mRNA levels, when com-
pared with primary meningiomas. Furthermore, NDRG2 gene
expression was found to be significantly decreased by 3.7-fold
in atypical (grade II) meningiomas when compared with be-
nign (grade I) meningiomas [65]. Although the patient cohort
in this study was relatively small (n = 35), similar statistically
significant results were obtained by Lusis et al. (n = 49) who
identified NDRG2 as a tumor suppressor gene. Loss of
NDRG2 mRNA and protein levels was found in anaplastic
(grade III) meningiomas and in a clinically aggressive subset
of atypical (grade II) meningiomas, most likely caused by
NDRG2 CpG promoter methylation [66].
Although these studies found a strong relationship between
loss ofNDRG2 expression and tumor grade/recurrence, a larg-
er study by Ongaratti et al. (n = 60) did not observe this effect
using immunohistochemistry [67]. The lack of reproducibility
could have been caused by the small number of meningiomas
with invasive and aggressive characteristics in this study (n =
12 for tumor grades II and III combined), or by the fact that the
two studies used different antibodies for immunohistochemis-
try. It is therefore still likely that loss of NDRG2 expression is
related to tumor aggressiveness, although it is difficult to draw
any conclusions regarding the correlation with protein expres-
sion. Functionally, it has been described that NDRG2 has an
antiproliferative effect, so loss of NDRG2would be beneficial
for tumor growth. Combining these findings, we hypothesize
that NDRG2 should be considered a tumor suppressor gene in
meningiomas.
Kotipatruni et al. obtained data suggesting thatNDRG4 has a
proto-oncogenic role in aggressive meningioma. Using in vitro
models, they showed that NDRG4-silencing induced apoptosis
and reduced the invasive potential of the meningioma cell lines
IOMM-Lee and CH-157 MN. Thus, it seems that NDRG4 is
necessary for meningioma cells to survive [64, 68]. No other
(clinical) studies are available that investigate NDRG4 in the
context of meningioma, so it is unclear whether NDRG4 is
indeed involved in meningioma pathology in patients.
Neuroblastoma
Neuroblastoma is typically a childhood cancer, accounting for
approximately 10% of all pediatric cancers. The tumor is de-
rived from neural crest cells of the sympathetic nervous sys-
tem, but the exact pathological mechanism remains unknown
[69]. NDRG1 likely serves as a tumor suppressor in neuro-
blastoma development. mRNA and protein expression were
investigated in 48 tissue specimens from neuroblastoma pa-
tients, and low NDRG1 expression was significantly associ-
ated with prognostic factors such as primary tumor size,
MYCN amplification, and poor prognosis [70].NDRG1-over-
expression in the c-Myc-overexpressing neuroblastoma cell
line SK-N-MC caused reduced cell size and reduced colony
formation, confirming the tumor-suppressive role of NDRG1
[71]. NDRG1 expression in neuroblastoma cells can also be
induced by the transcription factor forkhead box D3
(FOXD3), which has a lower expression in neuroblastoma
tissues and cell lines (SH-SY5Y and SK-N-SH) [69].
In patients with neuroblastoma (n = 42), high NDRG2 ex-
pression resulted in significantly longer survival. NDRG2 ex-
pression was lower in neuroblastoma tissue and cells than
Fig. 3 Functional pathways influenced by NDRG1, NDRG2, NDRG3,
and NDRG4. a Distinct functional pathways for NDRG1, NDRG2, and
NDRG4. b Shared functional pathways induced by ischemia and stress
involving more than one NDRG family member. LDL, low-density lipo-
protein; Olig2, oligodendrocyte lineage transcription factor 2; PRA1,
Prenylated Rab Acceptor 1; BDNF, brain-derived neurotrophic factor;
AP-1, activator protein 1; Snap25, synaptosomal-associated protein 25;
SGK1, serum/glucocorticoid-regulated kinase 1; OL, oligodendrocyte;
GLAST, glutamate transporter glutamate aspartate transporter; GLT-1,
glutamate transporter 1
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normal dorsal ganglia and was significantly associated with
the tumor suppressor intelectin 1 (ITLN1) [72]. To determine
the functional role of NDRG2 in neuroblastoma, overexpres-
sion of NDRG2 was induced in the neuroblastoma cell lines
SK-N-SH and SH-SY5Y, which resulted in an increased ex-
pression of the tumor suppressor gene protocadherin 17 and
differentiation-related genes such as Rsu1 and Smurf1, and
the decreased expression of proliferation-related genes such
as CYR61. NDRG2 overexpression could thereby reduce cell
proliferation compared with control cells [73].
Glioma
Malignant gliomas are the most common malignant primary
brain tumor and also the most aggressive tumor type of the
nervous system [74]. Comparedwith the abovementioned ner-
vous system malignancies, NDRG expression profiles in glio-
blastoma have been extensively researched. Gliomas are ei-
ther astrocytic, oligodendrocytic, or a mix of these cell types
from origin, and they can be classified from WHO grades I–
IV according to malignancy. Different designations are used
for gliomas in the literature, including astrocytoma (grades I–
II), anaplastic astrocytoma (grade III), and glioblastoma
(grade IV) [75]. In this article, we will use the WHO grading
system to indicate tumor malignancy and to compare different
studies.
The NDRG1 expression pattern was investigated in tissue
sections of grade II glioma (n = 40) where moderate-to-high
NDRG1 protein expression was found as a prognostic factor
for reduced risk of glioma progression and progression-free
survival. However, overall survival of glioblastoma patients
was not significantly affected by NDRG1 expression levels
[76]. A larger study investigating different glioma grades (n =
168) found reduced NDRG1 expression in gliomas, which
was negatively correlated to glioma grade. This study reported
a significantly lower overall survival in patients with low
NDRG1 expression, independent of other prognostic indica-
tors (e.g. tumor grade) [77]. Cell line experiments in glioma
cells showed that NDRG1 inhibits cell proliferation and inva-
sion and induced apoptosis. Additionally, tumorigenicity of
subcutaneously injected NDRG1-overexpressing glioma cells
was reduced in vivo [78], concluding that NDRG1 likely has a
tumor-suppressive function in glioma.
Contrary to these findings, Said et al. observed higher
NDRG1 mRNA and protein expression levels in grade IV
glioma (n = 15) compared with grade II glioma (n = 15) and
suggested that this is caused by the hypoxic state of the tumor,
as NDRG1 is a downstream target of hypoxia-inducible factor
1 (HIF-1). However, this study did not link NDRG1 expres-
sion to survival rate or prognosis [79]. Weiler et al. found that
hypoxia and radiotherapy induced NDRG1 expression in gli-
oma cells, leading to a poor response to alkylating chemother-
apy [80]. Blaes et al. confirmed this by observing that post-
surgically treated patients with genotoxic-induced NDRG1
expression had reduced overall survival, while patients that
had not been post-surgically treated had an increased overall
survival related to high NDRG1 expression [76]. Collectively,
these data suggest that NDRG1 might have properties of a
tumor suppressor gene in glioblastoma, but that upregulation
by genotoxic treatment will impair the response to chemother-
apy and lead to reduced overall survival.
NDRG2 has also been found as a candidate tumor suppres-
sor gene in glioma as NDRG2 expression was markedly re-
duced in grade IV glioma tissues (n = 27). Moreover, overex-
pression of NDRG2 in U373 and U138 (glioblastoma cell
lines) led to reduced cell proliferation [81]. Another study
reported NDRG2 expression as an independent prognostic
factor for overall survival in glioma patients. NDRG2 expres-
sion was investigated in grade I–IV glioma tissue samples
(n = 316) and was found to be decreased in more aggressive
glioma grades compared with healthy controls [82]. In addi-
tion, NDRG2 promotor methylation was found to be tumor-
specific and associated with shorter survival in patients who
survived less than 24 months (4.6 months, methylated;
7.8 months, non-methylated), but was not associated with
overall survival (n = 137) [83]. Three other studies confirmed
the finding that NDRG2 expression is lower in gliomas due to
NDRG2 promoter methylation. Tepel and colleagues [84] ob-
served decreased NDRG2 protein and mRNA expression in
grade IV gliomas compared with grade II and grade III glio-
mas (n = 67) and observed hypermethylation in 62% of grade
IV gliomas (n = 34). Zhou et al. [85] observed lower NDRG2
mRNA expression in glioma tissue (n = 53) compared with
adjacent healthy tissue (n = 26). In addition, the methylation
rate of the NDRG2 promoter was with 46.3% in glioma tissue
significantly different from the 18.2% in normal tissue.
Skiriute et al. analyzed grade I–IV gliomas (n = 137) and con-
firmed that gene methylation frequency increased in higher
grade gliomas and mRNA and protein expression decreased.
However, this study found no correlation between NDRG2
expression and promoter methylation. Clinical significance
was also investigated and revealed a significantly longer sur-
vival time for patients with unmethylated NDRG2 status, high
mRNA expression of NDRG2, and high protein NDRG2 ex-
pression, although they could not be used as separate prog-
nostic factors [86].
In contrast to NDRG2, the studies regarding expression of
NDRG4 in glioma show conflicting outcomes. One study
described increased NDRG4 expression, while others report
downregulation of NDRG4 in glioma [87–90]. Ding et al.
observed significantly decreased NDRG4 protein and
mRNA expression in glioma tissue (n = 49) compared with
normal tissue (n = 10), which was also confirmed using The
Cancer Genome Atlas (TCGA; n = 410) data [87], and by
Kolodziej et al. [89]. In addition, reduced NDRG4 protein
expression was found as a predictor for poor prognosis and
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reduced overall survival in both low- and high-grade gliomas
(n = 128) [90].
Contrary to these findings, Schilling et al. detected higher
NDRG4 expression in glioma grade IV tissue (n = 6) com-
pared with healthy brain tissue (n = 2). However, the number
of patients investigated in this study is too low to draw any
conclusions. Follow-up analysis focused on in vitro experi-
ments, concluding that NDRG4 is important for cell cycle
progression and cell viability [88]. Kolodziej et al. reported
a small increase in NDRG4 protein levels in glioma tissue as
observed with immunohistochemistry, mainly located in glia,
but this was not validated by any other methods. The authors
themselves propose that this finding is due to non-specific
staining [89]. NDRG4 thus seems to be a tumor suppressor
gene in glioma. However, considering that NDRG4 is exclu-
sively expressed in neurons, it is debatable whether NDRG4
would be of major influence in a glia-originated cancer.
Dysfunction of the NDRG familymembers can clearly lead
to pathological alterations, as is best described for NDRG1 in
CMT4D. However, neurodegenerative diseases like
Alzheimer’s disease and frontotemporal lobar degeneration
might also be influenced by NDRG1 or NDRG2, although
these mechanisms remain to be elucidated. NDRG3 has not
been described to be involved in any nervous system cancer
type. However, NDRG3 has been described in several other
cancer types, such as prostate cancer, non-small cell lung can-
cer, hepatocellular carcinoma, breast cancer, and laryngeal
squamous cell carcinoma [91–93]. Additional research is re-
quired to identify a potential role for NDRG3 within the ner-
vous system and nervous system malignancies. In the context
of nervous system cancers, NDRG1, NDRG2, and NDRG4
have been described to be tumor suppressor genes, although
some results are not consistent throughout different studies.
These discrepancies could be related to the use of different
antibodies for protein detection, small sample sizes, or differ-
ent interventions in patients, such as genotoxic treatments. All
in all, we can conclude that NDRG family members are im-
portant for normal functioning of the nervous system and that
alterations in gene expression can lead to disease conditions.
Conclusion
The NDRG family is largely represented in the nervous sys-
tem of multiple species. Expression already arises during em-
bryonic development and remains present during adulthood.
The NDRG family has been linked to differentiation and pro-
liferation processes, which might explain their role in devel-
opment. In spite of their involvement in similar processes, it is
important to note the diversity of the NDRGs regarding their
expression pattern and functional roles in the nervous system.
However, the NDRGs show specific expression patterns in
distinct cell types and they also have diverse functions in the
nervous system. Pathological alterations of the NDRGs, like
mutations and altered phosphorylation or expression levels,
can cause a variety of diseases, including neurodegenerative
diseases and nervous system cancers. Although some NDRGs
are specifically involved in a disease without contribution of
the other family members, a common feature of the NDRG
family seems their involvement in various cancer types.
Although most research currently focuses on NDRGs in can-
cer, it is important to keep in mind that the function of the
NDRGs is not restricted to cancer hallmarks, such as prolifer-
ation and apoptosis, but ranges from lipid and vesicle traffick-
ing to sodium channel clustering important for normal
neuronal/cellular functioning. Furthermore, all NDRGs
should be considered as individual genes, as their expression
patterns as well as their functions are mostly distinct.
Nonetheless, more research has to be done before we can
elucidate the exact role of each NDRG family member in
the nervous system.
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